MN SF4485

Establishes a psilocybin therapeutic use program administered by the Commissioner of Health for Minnesota residents 21 years or older diagnosed with qualifying medical conditions including PTSD, depression, substance use disorders, anxiety, and chronic pain

Requires patients to obtain written certification from a Minnesota-licensed physician, undergo health screening for contraindications, complete informed consent, and pay annual fees for 12-month registration valid starting January 1, 2027

Creates licensing framework for registered facilitators (must be licensed mental health professionals), registered suppliers who cultivate psilocybin, and certified testing facilities, with initial program limited to 20-50 facilitators and no more than 1,000 patients during first three years

Reclassifies psilocybin and psilocin from Schedule I to Schedule IV controlled substances and provides civil and criminal protections for registered participants, including prohibitions on employment discrimination, housing discrimination, and custody denial based solely on program participation

Establishes a Psychedelic Medicine Advisory Committee with initial appointments by November 1, 2026, requires interagency agreement with Office of Cannabis Management for patient registries and facilitator licensing, and mandates program evaluation after the three-year pilot period